In the 17th line of the abstract of this recently published paper by N. Mertziotis et al., the correct word 'former' was inadvertently replaced by the word 'latter'.The correct sentence should read: 'Hypertrophic scars were observed in 18 men (51%) in the former group. In the circumcision group, no major…'. This error has now been corrected online and in the print edition.We offer our profound apologies to the readers for any confusion and misunderstanding due to our careless error.
Our objective is to describe a novel ligamentolysis approach using a subcoronal incision technique and to determine its safety and efficacy. During the last 7 years, 82 consecutive patients had penile augmentation surgery. Ligamentolysis, through a lower abdominal incision (V-Y plasty) in the first 35 males, was performed (Group A), followed by circumcision ligamentolysis in the next 47 males (Group B). The operation time, complications, and the preoperative and postoperative values of penile length and girth along with the self-esteem and relations questionnaire score as well as satisfaction score was calculated before and after the surgery, and a comparison was conducted between the groups. The mean age at presentation was 32 years (range: 18-56 years). Seventy-nine patients suffered from penile dysmorphophobia, and three patients had micropenises (length ,7.5 cm). The mean surgical times were 150.7 and 125.2 min for Groups A and B, respectively (P50.005). Postoperatively, four Group A patients and three Group B patients (11% versus 6%, respectively) experienced penile retraction (P50.453). Hypertrophic scars were observed in 18 men (51%) in the former group. In the circumcision group, no major wound complications were recorded. The length and girth improvements between the groups were similar. In terms of satisfaction and SEAR improvement, the resulting difference for both variables favored the circumcision group (P50.007 and ,0.001, respectively). With strict selection criteria, the circumcision ligamentolysis procedure compared to the V-Y plasty demonstrated improved results in terms of safety, operation time, retraction rate and cosmetic appearance without any compromise in the gained penile size. INTRODUCTIONFor centuries, penile size has been a source of major concern and anxiety to the male population. Despite that in the majority of men, penile length is within the normal range, the concern regarding its size may lead to low self-esteem, sexual dysfunction and even psychiatric disorders. The psychiatric term 'penile dysmorphophobia' has been introduced to describe the abnormal perception of penile size, although it has normal dimensions.The majority of patients who request penile augmentation are dysmorphophobic rather than micropenile men.1,2 However, augmentation phalloplasty is not always successful and occasionally leads to penile shortening.3,4 Moreover, the reported satisfaction rates are often poor, which is most likely because the formation of even small hypertrophic scars or keloids for these patients can reduce their inclination for surgery. Therefore, detailed counseling regarding the postoperative results and surgical complications is of utmost importance.5 Several penile augmentation surgical techniques have been proposed, and the most widely performed is the incision of the suspensory ligament (ligamentolysis) combined with V-Y plasty.
Herein, we report on our experience with six patients (0.3%) diagnosed with lymphoepithelioma-like bladder carcinoma (LELBC) over the past 15 years at our department. The mean age of the patients with LELBC was 73 years (range 69-80 years). All patients had at least pT2 disease. The primary treatment was transurethral resection of the bladder tumor, radical cystectomy (RC), and radiotherapy (RT) in one, two, and three patients, respectively. After a mean follow-up of 31 months (range 13-72 months), three patients are still alive. The predominant subtype was diagnosed in four patients, three of whom are alive at the time of writing, compared with the two patients in whom the focal subtype was diagnosed , both of whom are dead. Two of the living patients were treated with a bladder-preservation strategy. Our experiences suggest that RC may not be necessary in muscle invasive disease and that RT and chemotherapy may be reliable treatment options. The pathology report may be useful in selecting patients suitable for bladder-preservation treatment.
Purpose Prostate cancer (PCa) is one of the most frequently diagnosed malignancies worldwide. Hormonal deprivation therapy is a well-established treatment for locally advanced or metastatic diseases but exposes patients to the risk of osteoporosis and fragility fractures. Furthermore, the tropism of the PCa cells to osseous metastases increases the incidence of skeletal-related events (SREs). Methods A nonsystematic review of the international literature was performed in respect to the use of osteoclast inhibitors zoledronic acid (ZA) and denosumab (DEN) in PCa patients. Results DEN and ZA have proved their efficacy in preventing osteoporosis and bone mass loss in patients treated with hormonal therapy with no proven superiority of one agent over the other. However, the effectiveness in reducing fragility fractures has been proved only for DEN so far. In metastatic-free castrate-sensitive high-risk PCa patients, ZA has not shown any efficacy in preventing osseous metastasis, and evidence is lacking in favor or against the use of DEN. The use of osteoclasts inhibitors had no evident positive effect in overall and disease-specific survival in this group of patients. In advanced castrate-refractory malignancy, DEN has shown clinical superiority over ZA in preventing new SRE but not in overall survival. Conclusion Superiority of DEN over ZA has been proved only in advanced castrate refractory disease in terms of preventing new SRE. In the rest of the cases, the selection of either agent should be based on the clinical condition of each patient and the cost of the treatment.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.